Loading page
Loading page
Loading substance route
Early morning dosing is advised to minimize sleep disruption; afternoon or late-morning administration may result in insomnia and subsequent fatigue. Concurrent food intake delays peak plasma concentration by 2–4 hours, potentially affecting onset and sustained effect. Paradoxical drowsiness has been reported in some individuals.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Armodafinil is considered mildly addictive with low abuse potential. Animal self-administration studies suggest some reinforcing properties, and it produces psychoactive and euphoric effects comparable to methylphenidate, though psychological dependence appears uncommon among users.
The LD50 for armodafinil or modafinil in humans has never been reached. Clinical trials with 1000-1600mg of modafinil daily for 7-21 days produced no life-threatening effects. Intentional overdoses of 4000-5000mg in adults and accidental ingestion of 800mg by a three-year-old child did not result in death, though a 5000mg overdose caused severe headache, nausea, and tachycardia without lethal or long-term consequences.
Serious skin reactions including Stevens-Johnson syndrome can develop in rare cases; these are hypersensitivity reactions requiring immediate medical attention if any rash develops.
Hallucinations and mania are listed as possible side effects, particularly at overdose levels. These effects appear uncommon at typical therapeutic or recreational doses.
Armodafinil is the isolated R-enantiomer of the racemic wakefulness-promoting agent modafinil. It was developed by Cephalon Inc., a pharmaceutical company that later became a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. The compound received approval from the United States Food…
Classified as a prescription-only medicine or prescription animal remedy under the Poisons Standard. Defined as a substance whose use or supply should be by or on the order of persons permitted by State or Territory legislation to prescribe, available only from a pharmacist on prescription.
Listed in Anlage 1 of the Arzneimittelverschreibungsverordnung (AMVV), the German Prescription Ordinance. Legal possession and dispensing requires a valid prescription from an authorized prescriber.
Not a licensed medicine and not controlled under the Misuse of Drugs Act 1971. Legal status under the Psychoactive Substances Act 2016 remains uncertain, as racemic modafinil is a licensed prescription-only medicine in the UK. Personal possession without prescription may not constitute a criminal offense, and legal import for personal use may be permissible under Section 13 of the Medicines Act 1968.
Listed as a Schedule F prescription drug under the Food and Drug Regulations. May be lawfully prescribed for both human and veterinary use.
Not directly scheduled as of 2021, but considered related to modafinil which is classified as a doping agent and will appear on laboratory tests. Simple possession is not a criminal offense but carries administrative penalties including fines and confiscation. Importing or exporting without a valid medical prescription constitutes a criminal offense punishable by two to seven years imprisonment.
Controlled under the Controlled Substances Act as a Schedule IV substance, indicating accepted medical use with low potential for abuse relative to Schedule III drugs. Purchasing, selling, or possessing armodafinil without a valid prescription or DEA license is illegal.
14 sources cited